ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
Home » Archive by Category

Syndication

Manager, Regulatory Affairs (Pacific Beach)

April 29, 2016 – 3:13 pm

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Staff Accountant (Pacific Beach)

April 29, 2016 – 3:10 pm

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Clinical Research Associate (Pacific Beach)

April 29, 2016 – 3:08 pm

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Production Associate II – Reference Standards & Controls (Sorrento Valley)

April 29, 2016 – 2:11 pm

Invivoscribe Technologies, Inc., is a privately-held corporation dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular research, molecular diagnostics, and personalized molecu […

Laboratory Technician (San Diego)

April 29, 2016 – 1:43 pm

EnviroMatrix Analytical, Inc.(EMA,Inc.), an analytical laboratory leader in San Diego, is seeking an individual who is hard working, reliable, and has a strong science background to assist in laboratory procedures. EMA, Inc. is an equal opportunity e […

Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results

April 29, 2016 – 12:00 pm

Conference Call and Webcast Scheduled For Thursday, May 5, 2016

SAN DIEGO, April 29, 2016 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants can access the live conference call by dialing 877-876-9174 (US) or 785-424-1669 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company’s website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-695-2533 (US) or 402-530-9029 (International) using the conference ID: NBIX. The call will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Chemist Position (Carlsbad)

April 29, 2016 – 11:44 am

Our client, a leading pharmaceutical company, is seeking a Production Chemist to join their team in Carlsbad, CA. Please send resumes in Word format.
Job Duties and Responsibilities:
Preparation of production related solutions
Synthesize and purif […

Sr Director, Market Insights & Strategy – Illumina, Inc. – San Diego, CA

April 29, 2016 – 9:54 am

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 29 Apr 2016 16:54:05 GMT
– View all San Diego jobs

DURECT Announces Closing of Public Offering of Common Stock

April 29, 2016 – 9:15 am

CUPERTINO, Calif., April 29, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters pursuant to their option.  All of the shares in the offering were sold by DURECT.  The gross proceeds to DURECT from this offering were approximately $17.3 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT.

Stifel acted as sole book-running manager for the offering and Laidlaw & Company (UK) Ltd. acted as co-manager. 

Felix Theeuwes, our Chairman and Chief Scientific Officer, and David Hoffmann, one of our directors, purchased an aggregate of 360,000 shares of common stock in the offering, at the public offering price, for an aggregate purchase price of $450,000.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and is effective.  A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov.  When available, copies of the final prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About DURECT Corporation

DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program.  Its drug development expertise is being applied primarily to the fields of pain management, CNS disorders, acute organ injury and metabolic diseases such as NAFLD/NASH.  DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs.  Late stage development programs of this nature include POSIMIR® (SABER®-Bupivacaine) and REMOXY® (ORADUR®-oxycodone).  DURECT’s Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development.  DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

NOTE: POSIMIR®, ORADUR® and SABER® are trademarks of DURECT Corporation. REMOXY, POSIMIR and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “may,” “should,” “could,” “will,” “would,” and “will be,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause the Company’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the final prospectus supplement, which has been filed with the SEC, and the risk factors incorporated by reference therein from the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

 

 

SOURCE DURECT Corporation

Entry Level Positions (In AND Outside the lab)

April 29, 2016 – 9:10 am

We have multiple openings for entry level candidates.
Whether you want to be on the bench/inside the lab setting
Techniques may include (but are not limited to): buffers, reagents, solutions, PCR, HPLC, in vivo, in vitro, gel electrophoresis, centr […